Abstract：
The observation that 2-deoxy-2[18F]fluoro-D-glucose-positron emission tomography/magnetic resonance imaging ([18F]F-FDG-PET/MRI) revealed high-grade arterial wall FDG uptake, without arterial wall thickening with contrast-enhancement, in a considerable number of c-TA patients in our previous study, encouraged us to compare patients with both PET and MR angiography (MRA) positives, with those with PET positive but MRA negative. Our aim was to evaluate the relevance of these two imaging modalities together.
A three-center cross-sectional study with 17 patients who fulfilled the EULAR/PRINTO/PReS criteria for c-TA and who underwent [18F]F-FDG-PET/MRI was previously performed. Herein we compared patients/vessels with positive PET (arterial wall 18F-FDG uptake higher than liver) and positive MRA (arterial wall thickening with contrast-enhancement)-group 1, with those with positive PET but negative MRA-group 2.
Median disease duration of 17 c-TA patients was 10.4 years. Nine patients were classified as group 1 and six as group 2. Median of metabolic inflammatory volume (MIV) of all arterial segments was significantly higher in group 1 (2346 vs. 1177 cm3; p = 0.036). Fifty-four (19%) from 284 available arterial segments presented positive findings in vessel wall in one or both images. Positive findings were concordant between PET and MRA in only 13% arterial segments (group 1); most changes (28-59.6%) that were discordant between both images, were positive in PET and negative in MRA (group 2).
Our study demonstrated that [18F]F-FDG-PET/MRI added information about inflammation in vessel wall of c-TA patients. Prospective multicenter studies are needed in order to get solid data to guide immunosuppressive tapering and withdrawal.
A three-center cross-sectional study with 17 patients who fulfilled the EULAR/PRINTO/PReS criteria for c-TA and who underwent [18F]F-FDG-PET/MRI was previously performed. Herein we compared patients/vessels with positive PET (arterial wall 18F-FDG uptake higher than liver) and positive MRA (arterial wall thickening with contrast-enhancement)-group 1, with those with positive PET but negative MRA-group 2.
Median disease duration of 17 c-TA patients was 10.4 years. Nine patients were classified as group 1 and six as group 2. Median of metabolic inflammatory volume (MIV) of all arterial segments was significantly higher in group 1 (2346 vs. 1177 cm3; p = 0.036). Fifty-four (19%) from 284 available arterial segments presented positive findings in vessel wall in one or both images. Positive findings were concordant between PET and MRA in only 13% arterial segments (group 1); most changes (28-59.6%) that were discordant between both images, were positive in PET and negative in MRA (group 2).
Our study demonstrated that [18F]F-FDG-PET/MRI added information about inflammation in vessel wall of c-TA patients. Prospective multicenter studies are needed in order to get solid data to guide immunosuppressive tapering and withdrawal.
摘要：
观察到2-脱氧-2[18F]氟-D-葡萄糖-正电子发射断层扫描/磁共振成像（[18F]F-FDG-PET/MRI）显示高等级的动脉壁FDG摄取，没有对比增强的动脉壁增厚，在我们之前的研究中，在相当数量的c-TA患者中，鼓励我们比较PET和MR血管造影（MRA）阳性的患者，PET阳性但MRA阴性的患者。我们的目的是一起评估这两种成像方式的相关性。
先前对17例符合EULAR/PRINTO/PReSc-TA标准并接受[18F]F-FDG-PET/MRI的患者进行了一项三中心横断面研究。在这里，我们比较了PET阳性（动脉壁18F-FDG摄取高于肝脏）和MRA阳性（对比增强的动脉壁增厚）组1的患者/血管，PET阳性但MRA阴性的患者组2。
17例c-TA患者的中位病程为10.4年。9例患者被归类为第1组，6例被归类为第2组。在第1组中，所有动脉段的代谢性炎症体积（MIV）的中位数均显着较高（2346vs.1177cm3；p=0.036）。在一个或两个图像中，来自284个可用动脉段的54个（19％）在血管壁中呈现阳性发现。PET和MRA的阳性结果仅在13％的动脉段（第1组）之间是一致的；大多数变化（28-59.6％）在两个图像之间是不一致的，PET阳性，MRA阴性（第2组）。
我们的研究表明，[18F]F-FDG-PET/MRI增加了c-TA患者血管壁炎症的信息。需要进行前瞻性多中心研究，以获得可靠的数据来指导免疫抑制逐渐减少和戒断。
先前对17例符合EULAR/PRINTO/PReSc-TA标准并接受[18F]F-FDG-PET/MRI的患者进行了一项三中心横断面研究。在这里，我们比较了PET阳性（动脉壁18F-FDG摄取高于肝脏）和MRA阳性（对比增强的动脉壁增厚）组1的患者/血管，PET阳性但MRA阴性的患者组2。
17例c-TA患者的中位病程为10.4年。9例患者被归类为第1组，6例被归类为第2组。在第1组中，所有动脉段的代谢性炎症体积（MIV）的中位数均显着较高（2346vs.1177cm3；p=0.036）。在一个或两个图像中，来自284个可用动脉段的54个（19％）在血管壁中呈现阳性发现。PET和MRA的阳性结果仅在13％的动脉段（第1组）之间是一致的；大多数变化（28-59.6％）在两个图像之间是不一致的，PET阳性，MRA阴性（第2组）。
我们的研究表明，[18F]F-FDG-PET/MRI增加了c-TA患者血管壁炎症的信息。需要进行前瞻性多中心研究，以获得可靠的数据来指导免疫抑制逐渐减少和戒断。
